|
|
|
|
|
|
eTheRNA Immunotherapies Selects Precision NanoSystems’ NxGen Technology for GMP Manufacturing
|
Vancovuer, BC, August 19, 2020--Precision NanoSystems Inc. (PNI) and eTheRNA Immunotherapies NV (eTheRNA) have signed a license and supply agreement for the development and manufacture of immunotherapies by eTheRNA using its proprietary mRNA TriMix platform.PNI's Clinical Solutions team supported eTheRNA with formulation development and scale-up and will conduct technology transfer to a manufacturing site for GMP production of eTheRNA's lead immunotherapy candidate.
|
|
|
|
|